
Opinion|Videos|April 4, 2025
Standardizing CRS Management and Ensuring Smooth Transitions of Care in Bispecific Therapy
Experts discuss why it is critical to have standardized protocols in place for managing cytokine release syndrome (CRS) in patients receiving bispecific antibodies, outlining the key components of an effective CRS management protocol as well as best practices for transitions of care between settings when administering and managing bispecifics.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- Why is it critical to have standardized protocols in place for managing CRS in patients receiving bispecific antibodies?
- What are the key components of an effective CRS management protocol?
- What are best practices for transitions of care between settings when administering and managing bispecifics?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
In Vivo CAR T Takes Center Stage, With Results Shared for 4 MRD-Negative Patients
2
Price Transparency With Gaps: Assessing the Completeness of Payer Transparency in Coverage Data
3
Camizestrant-Related Photopsia Mostly Mild, Nondisabling in Patients With Advanced Breast Cancer: Adam Brufsky, MD, PhD
4
T-DXd Delivers Strong Breast Cancer Outcomes Across Groups
5














































